Urolog. pro Praxi, 2002; 4: 150-153

Čo je nové v benígnej prostatickej hyperplázii?

MUDr. Jozef Marenčák Ph.D
Urologické oddelenie NsP Skalica

Keywords: LUTS/BPH, basic science, diagnosis, epidemiology and natural history, therapy.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marenčák J. Čo je nové v benígnej prostatickej hyperplázii? Urol. praxi. 2002;3(4):150-153.

V poslednom desa»ročí bola venovaná významná pozornos» problematike príznakov dolných močových ciest (LUTS - lower urinary tract symptoms) a benígnej prostatickej hyperplázii (BPH). V tomto článku sú sprehµadnené niektoré najvýznamnejąie príspevky (buď publikované, a/alebo prednesené na medzinárodných konferenciách počas celého roku 2001) rozdelené do hlavných kategórií.

Kµúčové slová

LUTS/BPH, základný výskum, epidemiológia, diagnostika a prirodzený vývoj, liečba.

What´s new in benign prostatic hyperplasia?

The topic of lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) has received significant attention from basic, translational and clinical researchers over the past decade, and the year 2001 was no different. In this chapter are reviewed some of the most significant contributions published and/or presented at international meetings throughout the year, divided into major categories.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Burinsky D, Williams J, Thornquest A. Mass spectral fragmentation reactions of a therapeutic 4 - azasteroid and related compounds. J. Am. Soc. Mass. Spectrom. 2001; 12: 385-398. Go to original source... Go to PubMed...
    2. Calvert R, Thompson C, Khan M. Alterations in cholinergic and purinergic signaling in a model of the obstructed bladder. J Urol 2001; 166: 1530-1533. Go to original source... Go to PubMed...
    3. Delakas D, Lianos E, Keryotis I. Finasteride: a long - term follow - up in the treatment of recurrent hematuria associated with benign prostatic hyperplasia. Urol Int 2001; 67: 69-72. Go to original source... Go to PubMed...
    4. Eckhardt M, van Venrooij G, van Melik H. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well - being J Urol 2001; 166: 563-568. Go to original source... Go to PubMed...
    5. Eckhardt M, van Venrooij G, van Melik H. Symtpoms and quality of life versus age, prostate volum, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2001; 57: 695-700. Go to original source... Go to PubMed...
    6. Hald T. Urodynamics in benign prostatic hyperplasia: a survey. Prostate, 1989; (suppl. 2): 69-77. Go to original source... Go to PubMed...
    7. Hess D, Marks L, Dorey F. Quantification of prostatic androgens. Part 1: method using needle biopsy specimens. J Urol 2001; 165 (suppl. 5): 379.
    8. Hindley R, Mostafid A, Brierly R. The 2-year symptomatic and urodynamic results of a prospective randomised trial of interstitial radiofrequency therapy vs transurethral resection of the prostatae. BJU Int. 2001; 99: 217-220. Go to original source... Go to PubMed...
    9. Horňák M, Breza J, Bárdoą A. Benígna prostatická hyperplázia: postavenie klasických operačných postupov na Slovensku. Urológia 2000; 2: 31-35.
    10. Kaplan S, Holtgrewe H, Bruskewitz R. Comparison of the efficacy and safety of finasteride in the older versus younger men with benign prostatic hyperplasia. Urology 2001; 57: 1073-1077. Go to original source... Go to PubMed...
    11. Levin M. Bladder dysfunction: morphological, biochemical and molecular changes. Abstracts LUTS: the paradigm shift -, ,new perspectives in aetiology and outcome". XVIIth Congress of the European Association of Urology, Birmingham, United Kingdom, February 23.-26. 2002: 6-7.
    12. Marks L, Macairan M, Hess D. Quantification of prostatic antigens. Part 2: effect of Saw Palmetto herbal blend. J Urol 2001; 165 (suppl. 5): 378. Go to PubMed...
    13. Marks L, Hess D, Forey F. Tissue effects of Saw Palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 2001; 57: 999-1005. Go to original source... Go to PubMed...
    14. Meigs J, Mohr B, Barry M. Risk factors for clinical benign prostatic hyperplasia in a community - based population of healthy aging men. J Clin Epidemiol 2001; 54: 935-944. Go to original source... Go to PubMed...
    15. Melke C, Manseck A, Hakenberg O. Is transurethral vaporesection of the prostate better than standard transurethral resection? Eur Urol 2001; 39: 551-557. Go to original source... Go to PubMed...
    16. Michel M, Goepel M. Potential role of alfa1 - adrenoceptors in the aetiology of LUTS. Eur Urol 2001; 39 (suppl. 3): 20-25. Go to original source... Go to PubMed...
    17. Mustonen S, Ala-Houhala I, Tammela T. Long - term renal dysfunction in patients with acute urinary retention. Scand. J Urol Nephrol 2001; 35: 44-48. Go to original source... Go to PubMed...
    18. Parekh M, Lobel R, O´Connor L. Protective effect of vitamin E on the response of the rabbit bladder to partial outlet obstruction. J Urol 2001; 166: 341-346. Go to original source... Go to PubMed...
    19. Roehrborn C, Malice M, Cook T. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: comprihensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001; 58: 210-216. Go to original source... Go to PubMed...
    20. Roehrborn C. Benign prostatic hyperplasia. In: Shah J. Urology highlights 2001-2002, 2002: 5-17.
    21. Schroder A, Kogan B, Lieb J. Increased blood flow after catheterization and drainage in the chronically obstructed rabbit urinary bladder. Urology 2001; 58: 295-300. Go to original source... Go to PubMed...
    22. Schroder A, Chichester P, Koban B. Effect of chronic bladder outlet obstruction on blood flow of the rabbit bladder. J Urol 2001; 165: 640-646. Go to original source... Go to PubMed...
    23. Sironi D, Levorato C, Gianfranco D. Managing the consequences of obstruction. Eur Urol 2000; 37: 103.
    24. Tubaro A, Carter S, Hind A. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol 2001; 166: 172-176. Go to original source... Go to PubMed...
    25. Tuhkanen K, Heino A, Ala-Opas M. Two-year follow-up results of a prospective randomised trial comparing hybrid laser prostatectomy with TURP in the treatment of big benign prostates. Scand. J Urol Nephrol 2001; 35: 200-204. Go to original source... Go to PubMed...
    26. Utkan T, Erden F, Yilidz F. Chronic ethanol consumption impairs adrenoceptor- and purinoceptor- mediated relaxations of isolated rat detrusor smooth muscle. BJU Int. 2001; 88: 278-283. Go to original source... Go to PubMed...
    27. Wei J, Schottenfeld D, Cooper K. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol 2001; 165: 1521-1525. Go to original source... Go to PubMed...
    28. Yang Q, Peters T, Donovan J. Transurethral incision compared with transurethral resection of the prostate for bladder outlet construction: a systematic review and meta - analysis of randomised controlled trials. J Urol 2001; 165: 1526-1532. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.